erlotinib has been researched along with verubulin in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (verubulin) | Trials (verubulin) | Recent Studies (post-2010) (verubulin) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 23 | 3 | 17 |
| Protein | Taxonomy | erlotinib (IC50) | verubulin (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0028 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.0056 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0084 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 1 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhary, S; Doshi, A; Gangjee, A; Hamel, E; Ihnat, M; Luckett-Chastain, L; Mooberry, SL | 1 |
1 other study(ies) available for erlotinib and verubulin
| Article | Year |
|---|---|
Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2021 |